| アブストラクト | OBJECTIVE: To explore the healthcare resource utilization (HCRU) and costs for patients with progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with [(177)Lu]Lu-DOTA-TATE and matched patients treated with somatostatin analogs (SSAs), chemotherapy, or targeted therapies. METHODS: Hospital Episode Statistics (HES) dataset 2016-2018 was used to compare HCRU and costs between the two cohorts. The [(177)Lu]Lu-DOTA-TATE cohort included patients assigned with a diagnosis code relevant to GEP-NET, a procedure code for imaging or SSAs, and a subsequent code for radionuclide therapy. The non-[(177)Lu]Lu-DOTA-TATE cohort included patients assigned with a diagnosis code relevant to GEP-NET who had an increased frequency of SSAs or switched from SSAs to chemotherapy or targeted therapies. Cohorts were matched on propensity scores with sex, age at disease progression, and Charlson Comorbidity Index as parameters. Healthcare Resource Group codes were used for costing. RESULTS: A total of 199 matched patients were included. The [(177)Lu]Lu-DOTA-TATE cohort had lower overall costs ( pound1,882,028 vs. pound3,016,321; p < .0001), non-elective inpatient spells (289 vs. 611 days) and costs ( pound849,569 vs. pound1,707,109; p < .0001 for both), Accident & Emergency costs ( pound41,978 vs. pound62,480; p = .0013), and average length of stay for overall inpatient spells (14.2 vs. 23.3 days; p = .1092) compared with the non-[(177)Lu]Lu-DOTA-TATE cohort. CONCLUSIONS: These analyses indicate significantly lower overall costs and HCRU for progressive GEP-NET patients treated with [(177)Lu]Lu-DOTA-TATE. Current research reveals that future real-world analyses would further benefit from using additional databases linked to the HES dataset such as the Clinical Practice Research Datalink and/or National Cancer Registration and Analysis Service database. |
|---|
| 投稿日 | 2022/4/15 |
|---|
| 投稿者 | Cox, Tony; O'Connell, Matthew; Leeuwenkamp, Oscar; Palimaka, Stefan; Reed, Nicholas |
|---|
| ジャーナル名 | Current medical research and opinion |
|---|
| 組織名 | Open Health, Marlow, United Kingdom.;Advanced Accelerator Applications/A Novartis Company, Geneva, Switzerland.;Advanced Accelerator Applications/A Novartis Company, London, United Kingdom.;Beatson Oncology Centre, Glasgow, United Kingdom. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35418254/ |
|---|
